Search International and National Patent Collections
Refine Search
Query Tree
Save query
A private query is only visible to you when you are logged-in and can not be used in RSS feeds
Results 1-10 of 10,226 for Criteria:CHEM:(FBPFZTCFMRRESA-UHFFFAOYSA-N) Office(s):all Language:en Stemming: false
Filters
1 2 3 4 5 6 7 8 9 10 11 12
Page: / 1023
Analysis
List Length
TitleCtrPubDate
Appl.NoApplicantInventorInt.Class
Ifosfamide-mesna lyophilizate and process for its preparation
US25.09.1990
07325883Asta Pharma AGSauerbier Dieter
A61K 9/00
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9
Medicinal preparations characterised by special physical form

An ifosfamide-mesna lyophilizate consists substantially of ifosfamide, 0.1-1.0 parts by weight of mesna and 0.1 to 17 parts by weight of hexitol. The product is obtained by freeze drying an aqueous or aqueous-ethanolic solution of ifosfamide and mesna.


HEXITOL DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
EP12.05.1982
81305161CHINOIN GYOGYSZER ES VEGYESZETI TERMEKEK GYARA RT.ELEKES, ILONA
C07C 69/63
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
C
ACYCLIC OR CARBOCYCLIC COMPOUNDS
69
Esters of carboxylic acids; Esters of carbonic or haloformic acids
62
Halogen-containing esters
63
of saturated acids
Hexitols of the general formula (wherein the hexitol skeleton corresponds to dulcitol, mannitol or iditol, R@ represents a halogen atom, R<3> represents a hydroxy group, or R<2> and R<3> together form an oxygen atom; R represents a free carboxy containing saturated or unsaturated alkylcarbonyl group with 4 to 10 carbon atoms, a free carboxy containing arylcarbonyl group with 8 to 12 carbon atoms or a free carboxy containing satiurated or unsaturated aralkylcarbonyl group with 9 to 11 carbon atoms) and Rs@ represents a hydrogen atom, a free carboxy containing saturated or unsaturated alkylcarbonyl group with 4 to 10 carbon atoms, a saturated or unsaturated C2-10 alkylcarbonyl group, an alkoxycarbonyl containing saturated or unsaturated alkylcarbonyl group with 4 to 10 carbon atoms, a saturated or unsaturated C8-10 aralkylcarbonyl group, a free carboxy containing arylcarbonyl group with 8 to 12 carbon atoms or a free carboxy containing saturated or unsaturated aralkylcarbonyl group with 9 to 11 carbon atoms) and salts thereof possess tumour inhibiting activity. The hexitols of the present invention are prepared by hydrogenation of a corresponding benzyloxycarbonyl containing 1,2-5,6-dianhydrohexitol, reaction of 1,2-5,6-dianhydrohexitol with a dicarboxylic acid anhydride and halogenation of a corresponding 1,2-5,6-dianhydrohexitol.

IFOSFAMIDE-MESNA-LYOPHILIZED COMPOSITION AND PROCESS TO PREPARE IT
EP27.09.1989
89103844ASTA PHARMA AKTIENGESELLSCHAFTSAUERBIER, DIETER
A61K 31/675
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
66
Phosphorus compounds
675
having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
The ifosfamide-mesna lyophilisate consists essentially of ifosfamide, 0.1 - 1.0 part by weight of mesna and 0.1 to 17 parts by weight of hexitol.

LYOPHILIZED COMPOSITION CONTAINING IFOSFAMIDE, AND PROCESS FOR ITS PREPARATION
EP04.05.1988
87115322ASTA PHARMA AKTIENGESELLSCHAFTSAUERBIER, DIETER
A61K 9/14
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9
Medicinal preparations characterised by special physical form
14
Particulate form, e.g. powders
1. A lyophilized preparation consisting of ifosfamide and 0.1 to 17 parts by weight hexitol per part by weight ifosfamide and, optionally, other standard pharmaceutical auxiliaries.

디안하이드로갈락티톨 및 디아세틸디안하이드로갈락티톨과 같은 치환된 헥시톨을 포함하는 준최적하게 투여되는 화학적 화합물의 치료상 이점을 향상시키기 위한 조성물 및 방법
KR25.02.2014
1020137006881델 마 파마슈티컬스 인코포레이티드브라운 데니스 엠.
A61K 31/336
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
335
having oxygen as the only ring hetero atom, e.g. fungichromin
336
having three-membered rings, e.g. oxirane, fumagillin
본 발명은 단일치료법으로서 효능을 증강시키거나 부작용을 감소시킴으로써, 이전에 준최적 치료 성능에 의해 제한을 받던 치료제의 치료 효능을 개선시키기 위한 방법 및 조성물을 설명한다. 이러한 방법 및 조성물은 디안하이드로갈락티톨 및 디아세틸디안하이드로갈락티톨과 같은 치환된 헥시톨에 특히 잘 적용된다.

VITAMIN E DERIVATIVE AND ITS PRODUCTION
JP17.10.2000
9387699CCI CORPANDO TAKAYUKI
C07D 311/72
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
311
Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
02
ortho- or peri-condensed with carbocyclic rings or ring systems
04
Benzo [b] pyrans, not hydrogenated in the carbocyclic ring
58
other than with oxygen or sulfur atoms in position 2 or 4
70
with two hydrocarbon radicals attached in position 2 and elements other than carbon and hydrogen in position 6
72
3, 4-Dihydro derivatives having in position 2 at least one methyl radical and in position 6 one oxygen atom, e.g. tocopherols
PROBLEM TO BE SOLVED: To produce a new vitamin E derivative having both an excellent antioxidant activity and excellent humectant properties by condensing a specific substituted alcohol with a specified polyhydric alcohol donor.

SOLUTION: This vitamin E derivative is represented by formula I (R1 to R4 are each H, a lower alkyl or a lower acyl; R5 is H, a lower alkyl, a lower acyl, benzyl or the like; X is a polyhydric alcohol; n is 0-4), e.g. 2-(2-glyceroxy) methyl-2,5,7,8-tetramethylchroman-6-ol. The vitamin E derivative represented by formula I can be produced by condensing (A) a 2-substituted alcohol represented by formula II with a polyhydric alcohol donor in which a leaving group is introduced into (B) hydroxyl group for bonding the component A thereto and other hydroxyl groups are protected with protecting groups. For example, the exemplified compound is obtained by reacting a 2-substituted alcohol represented by formula III as the component A with a glycerol donor represented by formula IV as the component B. The derivative represented by formula I is useful as various cosmetics, etc., effective in prevention of aging of skin, etc.

COPYRIGHT: (C)2000,JPO


Compositions comprising Cetrorelix acetate for the treatment of female infertility and gonadal protection
EP06.10.1999
99102340ZENTARIS IVF GMBHENGEL JÜRGEN PROF DR
A61K 38/00
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
Sterile freeze-dried cetrorelix acetate (a peptide described in EP299402) is used in the treatment of female infertility. Independent claims are also included for the following: (1) use of sterile freeze-dried cetrorelix acetate for protecting gonads against noxious agents that damage germ cells, e.g. radiation treatment and chemotherapy; (2) a composition comprising sterile freeze-dried cetrorelix acetate and optionally excipients for use in the treatment of female infertility; (3) a composition comprising sterile freeze-dried cetrorelix acetate and optionally excipients for protecting gonads against noxious agents that damage germ cells, e.g. radiation treatment and chemotherapy with cytostatic agents.

HYPOTENSIVE AGENT CONTAINING PENTITOL OR HEXITOL AS ACTIVE INGREDIENT
JP04.11.2005
2004125370THREE-B CO LTDYOSHINARI ATSUSHIRO
A61K 36/7
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
36
Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
06
Fungi, e.g. yeasts
07
Basidiomycota, e.g. Cryptococcus
PROBLEM TO BE SOLVED: To obtain a new ACE inhibitor having extremely high safety, and a new hypotensive agent having extremely high safety.

SOLUTION: The ACE (angiotensin converting enzyme) inhibitor contains a pentitol or a hexitol as an active ingredient. The most preferable active ingredients are mannitol and xylitol. Also, the ACE inhibitor and the hypotensive agent each contains the extract of Pleurotus comucopiae as an active ingredient. The ACE inhibitor does not has toxicity, does not affect living bodies, even when taken in a large amount, and furthermore has other advantages.

COPYRIGHT: (C)2006,JPO&NCIPI


EUKARYOTIC HOST CELL FOR EXPRESSION VITAMIN K DEPENDENT PROTEIN, EXPRESSION VECTOR IN EUKARYOTIC CELLS, METHOD FOR MAKING GAMMA-CARBOXYLATED VITAMIN K DEPENDENT PROTEIN AND METHOD FOR MAKING PHARMACEUTICAL COMPOSITION FOR COAGULATION INDUCTION OR STIMULATION OF COAGULATION INCREASE OR DECREASE
RU10.11.2009
2006110147/13ФЕНГЕ Кристель (SE)
C12N 15/63
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N
MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15
Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09
Recombinant DNA-technology
63
Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
FIELD: medicine. SUBSTANCE: vitamin K dependent protein is made by separating a cultivated eukaryotic cell that contains an expressing vector that contains a nucleic acid molecule coding vitamin K dependent protein and associated sequences regulating expression. The associated sequences contain the first promoter and the nucleic acid molecule coding gamma-glutamylcarboxylase, and the second promoter. The first promoter represents a pre-early promoter of human cytomegalovirus (hCMV), and the second promoter is a pre-early promoter SV40. Herewith the expressing relation of vitamin K dependent protein and gamma-glutamylcarboxylase is 10:1 to 250:1. EFFECT: invention allows for making gamma-carboxylated vitamin K dependent protein in production quantities. 29 cl, 5 dwg, 6 tbl, 7 ex

TNFスーパーファミリー受容体に対するスプライス切替オリゴマーならびに疾病治療における該オリゴマーの使用
JP16.04.2009
2008540193サンタリス ファーマ アー/エスサザニ、 ペーター エル.
A61K 31/7088
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
70
Carbohydrates; Sugars; Derivatives thereof
7088
Compounds having three or more nucleosides or nucleotides

TNF受容体(TNFR1およびTNFR2)ならびにTNFRスーパーファミリーのその他の受容体の発現を、これらの受容体をコードする前駆体mRNAのスプライシングを調整する化合物を使用して制御するための、方法および組成物が開示される。より具体的には、これらの化合物により上記受容体の膜貫通ドメインが除去され、TNF−α活性または関連リガンドの活性を低減するアンタゴニストとして作用する可溶性の受容体が生じる。TNF−α活性を低減することにより、TNF−α活性に関連した炎症性の疾病または状態を治療または改善する方法が提供される。同様に、他のリガンドに関連した疾病も類似の方法で治療することができる。特に、本発明の化合物は、インビボにおいて安定で、RNAに配列特異的にハイブリダイズし、かつその標的と共にRNaseHによる分解を受けない小さな分子である、スプライス−スプライス切替オリゴマー(SSO)である。


Results 1-10 of 10,226 for Criteria:CHEM:(FBPFZTCFMRRESA-UHFFFAOYSA-N) Office(s):all Language:en Stemming: false
Filters
1 2 3 4 5 6 7 8 9 10 11 12
Page: / 1023